Pharmacogenetics: Genetic approach supports cardiovascular safety of GLP1R agonists.
Irene
I
Fernández-Ruiz
D003327:Coronary Disease / Q000139:chemically induced / Q000235:genetics* / Q000517:prevention & control; D000067757:Glucagon-Like Peptide-1 Receptor / Q000235:genetics*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010597:Pharmacogenetics; D000071184:Pharmacogenomic Variants; D065840:Protective Factors; D018570:Risk Assessment; D012307:Risk Factors; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D000097789:Glucagon-Like Peptide-1 Receptor Agonists